A detailed history of Jones Financial Companies Lllp transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Jones Financial Companies Lllp holds 5 shares of BGNE stock, worth $895. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5
Previous 11 54.55%
Holding current value
$895
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$143.93 - $224.51 $863 - $1,347
-6 Reduced 54.55%
5 $1,000
Q2 2024

Aug 14, 2024

BUY
$129.52 - $174.32 $1,424 - $1,917
11 New
11 $1,000
Q4 2023

Feb 13, 2024

BUY
$158.67 - $201.58 $317 - $403
2 New
2 $0
Q1 2022

May 02, 2022

SELL
$146.52 - $269.56 $1,172 - $2,156
-8 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$248.56 - $389.34 $1,988 - $3,114
8 New
8 $2,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.6B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Jones Financial Companies Lllp Portfolio

Follow Jones Financial Companies Lllp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jones Financial Companies Lllp, based on Form 13F filings with the SEC.

News

Stay updated on Jones Financial Companies Lllp with notifications on news.